239 related articles for article (PubMed ID: 37153730)
1. Small extracellular vesicle-loaded bevacizumab reduces the frequency of intravitreal injection required for diabetic retinopathy.
Reddy SK; Ballal AR; Shailaja S; Seetharam RN; Raghu CH; Sankhe R; Pai K; Tender T; Mathew M; Aroor A; Shetty AK; Adiga S; Devi V; Muttigi MS; Upadhya D
Theranostics; 2023; 13(7):2241-2255. PubMed ID: 37153730
[TBL] [Abstract][Full Text] [Related]
2. Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.
Ozer F; Tokuc EO; Albayrak MGB; Akpinar G; Kasap M; Karabas VL
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1899-1906. PubMed ID: 35028761
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) and panretinal photocoagulation in the treatment of high-risk proliferative diabetic retinopathy.
Yang CS; Hung KC; Huang YM; Hsu WM
J Ocul Pharmacol Ther; 2013; 29(6):550-5. PubMed ID: 23495932
[TBL] [Abstract][Full Text] [Related]
4. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; MartÃnez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
5. Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review.
Zehden JA; Mortensen XM; Reddy A; Zhang AY
Curr Diab Rep; 2022 Oct; 22(10):525-536. PubMed ID: 36053385
[TBL] [Abstract][Full Text] [Related]
6. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.
Sohn EH; He S; Kim LA; Salehi-Had H; Javaheri M; Spee C; Dustin L; Hinton DR; Eliott D
Arch Ophthalmol; 2012 Sep; 130(9):1127-34. PubMed ID: 22965588
[TBL] [Abstract][Full Text] [Related]
7. Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats.
Ma J; Zhu T; Tang X; Ye P; Zhang Z
Clin Exp Ophthalmol; 2010 Dec; 38(9):875-84. PubMed ID: 20653693
[TBL] [Abstract][Full Text] [Related]
8. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy.
Arimura N; Otsuka H; Yamakiri K; Sonoda Y; Nakao S; Noda Y; Hashiguchi T; Maruyama I; Sakamoto T
Ophthalmology; 2009 May; 116(5):921-6. PubMed ID: 19410951
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
10. A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Nicholson BP; Schachat AP
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):915-30. PubMed ID: 20174816
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.
Spaide RF; Fisher YL
Retina; 2006 Mar; 26(3):275-8. PubMed ID: 16508426
[TBL] [Abstract][Full Text] [Related]
12. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy.
di Lauro R; De Ruggiero P; di Lauro R; di Lauro MT; Romano MR
Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):785-91. PubMed ID: 20135139
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.
Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A
Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Bevacizumab Injection Attenuates Diabetic Retinopathy in Adult Rats with Experimentally Induced Diabetes in the Early Stage.
Lv J; Chen MM; Mu ZH; Wang F; Qian ZY; Zhou L; Guo QT; Zhao ZM; Pan YP; Liao XY; Yang ZH; Cai N; Li SD; Zou YY
J Diabetes Res; 2018; 2018():9216791. PubMed ID: 29977927
[TBL] [Abstract][Full Text] [Related]
17. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Matsumoto M; Suzuma K; Maki T; Kinoshita H; Tsuiki E; Fujikawa A; Kitaoka T
Am J Ophthalmol; 2012 May; 153(5):896-902.e1. PubMed ID: 22265145
[TBL] [Abstract][Full Text] [Related]
18. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
Simunovic MP; Maberley DA
Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
[TBL] [Abstract][Full Text] [Related]
19. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.
Tan Y; Fukutomi A; Sun MT; Durkin S; Gilhotra J; Chan WO
Surv Ophthalmol; 2021; 66(6):926-932. PubMed ID: 33705807
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of neovascularization and expression shift of pro-/anti-angiogenic vascular endothelial growth factor isoforms after intravitreal bevacizumab injection in oxygen-induced-retinopathy mouse model.
Shi X; Zhao M; Xie WK; Liang JH; Miao YF; DU W; Li XX
Chin Med J (Engl); 2013 Jan; 126(2):345-52. PubMed ID: 23324288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
